AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
|Articles|November 20, 2007
Joanna Breitstein
Advertisement
Joanna Breitstein
Executive Editor
Joanna Breitstein is executive editor at Pharmaceutical Executive magazine, and has been with the publication since November 2000. During that time, she's interviewed countless CEOs and other pharma executives for cover stories and feature articles on all aspects of the development and commercialization of pharmaceuticals. In 2004, Joanna won a fellowship from the Kaiser Family Foundation to travel to Africa and report on AIDS drug distribution under President Bush's PEPFAR grant, resulting in a two-part series on the topic. Joanna also won a Neal Award, for excellence in business journalism, in 2002 for her cover story focusing on the coverage of diagnostics and pharmaceuticals, and a Grand Neal Award in 2001, for a cover story on patient advocacy in oncology. Before joining Pharmaceutical Executive, Joanna deepened her knowledge of the pharma industry and several treatment categories within the health and medical group at Ogilvy Public Relations Worldwide. She is also president of the international HUG Foundation, a 501c3 organization whose mission is to help needy orphans in Uganda.
Advertisement
Related to this article
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Advertisement
Advertisement
Trending on PharmExec
1
Understanding the Latest with MFN Pricing and What It Means to Pharma
2
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
3
The Battle to Own the GLP-1 Patient Journey
4
Novo Announces Drug Discovery Collaboration with Anthropic
5